| Emily Rose Houston, PHARMD | |
|
31 Three Mile Dr Ste 10, Kalispell, MT 59901-3099 | |
| (612) 760-3424 | |
| Not Available |
| Full Name | Emily Rose Houston |
|---|---|
| Gender | Female |
| Speciality | Pharmacist - Pharmacist Clinician (phc)/ Clinical Pharmacy Specialist |
| Location | 31 Three Mile Dr Ste 10, Kalispell, Montana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104604461 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1835P0018X | Pharmacist - Pharmacist Clinician (phc)/ Clinical Pharmacy Specialist | PHAPHALIC69569 (Montana) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Emily Rose Houston, PHARMD 305 Bismark St, Kalispell, MT 59901-9006 Ph: (612) 760-3424 | Emily Rose Houston, PHARMD 31 Three Mile Dr Ste 10, Kalispell, MT 59901-3099 Ph: (612) 760-3424 |
News Archive
The majority of men who use violence towards their partner struggle with serious mental health issues. We need to look at more than just the power relations between the sexes in order to understand and prevent domestic violence, says researcher.
A network of very fine blood vessels that connects bone marrow directly with the blood supply of the periosteum that was previously overlooked has now been discovered by Dr. Anika Grüneboom, a young researcher who is now working at Universitätsklinikum Erlangen.
The Greater New York City Affiliate of Susan G. Komen for the Cure® is kicking off a one-year celebration of its 20th anniversary with the publication of its first-ever eight-page full-color newsletter looking back on the past 20 years, recapping 2009 and gazing into the organization's future.
Vitae Pharmaceuticals, Inc., an integrated discovery and development company, today announced that it has earned a $14 million clinical milestone payment from Boehringer Ingelheim, one of the world's 20 leading pharmaceutical companies. Vitae's 11beta-hydroxysteroid dehydrogenase (HSD)-1 is targeted for the treatment of diabetes and metabolic syndrome-related diseases in a strategic alliance with Boehringer Ingelheim. The payment recognizes Boehringer Ingelheim's recent advancement of a small molecule inhibitor of 11beta-HSD-1 into Phase I clinical trials.
› Verified 1 days ago
Mr. Mark Steven Walters, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1370 Us Highway 2 E, Kalispell, MT 59901 Phone: 406-257-1274 Fax: 406-257-1268 | |
Rose Ellen Doepker, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 202 2nd Ave W, Kalispell, MT 59901 Phone: 406-257-4806 Fax: 406-756-5134 | |
Renee Wilkonski-larson, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 55 1st Ave En, Kalispell, MT 59901 Phone: 406-370-9877 | |
Danielle Perry, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 900 W Idaho St, Kalispell, MT 59901 Phone: 406-257-7556 | |
Dr. Amber Lynn Windnagle, PHARM D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1370 Us Highway 2 E, Kalispell, MT 59901 Phone: 406-257-1274 Fax: 406-257-1268 | |
Alan Marvin, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 170 Hutton Ranch Rd, Kalispell, MT 59901 Phone: 406-755-3911 |